Dasatinib
- Product NDC
- 82009-197
- Requested package NDC
- 82009-197-30
- 11-digit product format
- 820090197
- Labeler code
- 82009
- Product ID
- 82009-197_669a5206-88e3-1014-a561-aa33f2b7b3a7
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- dasatinib
- Dosage form
- TABLET, FILM COATED
- Route
- ORAL
- Labeler
- Quallent Pharmaceuticals Health LLC
- Application
- ANDA217217
- Marketing category
- ANDA
- Marketing start
- 2026-11-02
- Substance
- DASATINIB
- Active strength
- 140 mg/1
- Pharmacologic classes
- Cytochrome P450 3A4 Inhibitors [MoA], Kinase Inhibitor [EPC], Protein Kinase Inhibitors [MoA]
- NDC exclude flag
- No
- Listing certified through
- 2027-12-31
- Current FDA listing
- Yes
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A217217-001 | DASATINIB | DASATINIB | 20MG | TABLET / ORAL | AB | 2025-03-03 | |
| A217217-002 | DASATINIB | DASATINIB | 50MG | TABLET / ORAL | AB | 2025-03-03 | |
| A217217-003 | DASATINIB | DASATINIB | 70MG | TABLET / ORAL | AB | 2025-03-03 | |
| A217217-004 | DASATINIB | DASATINIB | 80MG | TABLET / ORAL | AB | 2025-03-03 | |
| A217217-005 | DASATINIB | DASATINIB | 100MG | TABLET / ORAL | AB | 2025-03-03 | |
| A217217-006 | DASATINIB | DASATINIB | 140MG | TABLET / ORAL | AB | 2025-03-03 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A217217-001 | AB |
| A217217-002 | AB |
| A217217-003 | AB |
| A217217-004 | AB |
| A217217-005 | AB |
| A217217-006 | AB |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A217217-001 | DASATINIB | 20MG | TABLET / ORAL | AB | 2025-03-03 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | A217217-002 | DASATINIB | 50MG | TABLET / ORAL | AB | 2025-03-03 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | A217217-003 | DASATINIB | 70MG | TABLET / ORAL | AB | 2025-03-03 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | A217217-004 | DASATINIB | 80MG | TABLET / ORAL | AB | 2025-03-03 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | A217217-005 | DASATINIB | 100MG | TABLET / ORAL | AB | 2025-03-03 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | A217217-006 | DASATINIB | 140MG | TABLET / ORAL | AB | 2025-03-03 | d4dbc9d85df4… | |
| 2026-10-15 13:18:30 | 2026-09 | A217217-001 | DASATINIB | 20MG | TABLET / ORAL | AB | 2025-03-03 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A217217-002 | DASATINIB | 50MG | TABLET / ORAL | AB | 2025-03-03 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A217217-003 | DASATINIB | 70MG | TABLET / ORAL | AB | 2025-03-03 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A217217-004 | DASATINIB | 80MG | TABLET / ORAL | AB | 2025-03-03 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A217217-005 | DASATINIB | 100MG | TABLET / ORAL | AB | 2025-03-03 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A217217-006 | DASATINIB | 140MG | TABLET / ORAL | AB | 2025-03-03 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | A217217-001 | DASATINIB | 20MG | TABLET / ORAL | AB | 2025-03-03 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A217217-002 | DASATINIB | 50MG | TABLET / ORAL | AB | 2025-03-03 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A217217-003 | DASATINIB | 70MG | TABLET / ORAL | AB | 2025-03-03 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A217217-004 | DASATINIB | 80MG | TABLET / ORAL | AB | 2025-03-03 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A217217-005 | DASATINIB | 100MG | TABLET / ORAL | AB | 2025-03-03 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A217217-006 | DASATINIB | 140MG | TABLET / ORAL | AB | 2025-03-03 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A217217-001 | DASATINIB | 20MG | TABLET / ORAL | AB | 2025-03-03 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A217217-002 | DASATINIB | 50MG | TABLET / ORAL | AB | 2025-03-03 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A217217-003 | DASATINIB | 70MG | TABLET / ORAL | AB | 2025-03-03 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A217217-004 | DASATINIB | 80MG | TABLET / ORAL | AB | 2025-03-03 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A217217-005 | DASATINIB | 100MG | TABLET / ORAL | AB | 2025-03-03 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A217217-006 | DASATINIB | 140MG | TABLET / ORAL | AB | 2025-03-03 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | A217217-001 | DASATINIB | 20MG | TABLET / ORAL | AB | 2025-03-03 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | A217217-002 | DASATINIB | 50MG | TABLET / ORAL | AB | 2025-03-03 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | A217217-003 | DASATINIB | 70MG | TABLET / ORAL | AB | 2025-03-03 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | A217217-004 | DASATINIB | 80MG | TABLET / ORAL | AB | 2025-03-03 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | A217217-005 | DASATINIB | 100MG | TABLET / ORAL | AB | 2025-03-03 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | A217217-006 | DASATINIB | 140MG | TABLET / ORAL | AB | 2025-03-03 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A217217-001 | DASATINIB | 20MG | TABLET / ORAL | AB | 2025-03-03 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A217217-002 | DASATINIB | 50MG | TABLET / ORAL | AB | 2025-03-03 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A217217-003 | DASATINIB | 70MG | TABLET / ORAL | AB | 2025-03-03 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A217217-004 | DASATINIB | 80MG | TABLET / ORAL | AB | 2025-03-03 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A217217-005 | DASATINIB | 100MG | TABLET / ORAL | AB | 2025-03-03 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A217217-006 | DASATINIB | 140MG | TABLET / ORAL | AB | 2025-03-03 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | A217217-001 | DASATINIB | 20MG | TABLET / ORAL | AB | 2025-03-03 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | A217217-002 | DASATINIB | 50MG | TABLET / ORAL | AB | 2025-03-03 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | A217217-003 | DASATINIB | 70MG | TABLET / ORAL | AB | 2025-03-03 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | A217217-004 | DASATINIB | 80MG | TABLET / ORAL | AB | 2025-03-03 | 6a471c1ec25d… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A217217-001 | AB | 1 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A217217-002 | AB | 1 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A217217-003 | AB | 1 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A217217-004 | AB | 1 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A217217-005 | AB | 1 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A217217-006 | AB | 1 | d4dbc9d85df4… |
| 2026-10-15 13:18:30 | 2026-09 | A217217-001 | AB | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A217217-002 | AB | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A217217-003 | AB | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A217217-004 | AB | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A217217-005 | AB | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A217217-006 | AB | 1 | c2088c7a36db… |
| 2026-09-14 22:38:34 | 2026-08 | A217217-001 | AB | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A217217-002 | AB | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A217217-003 | AB | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A217217-004 | AB | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A217217-005 | AB | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A217217-006 | AB | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A217217-001 | AB | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A217217-002 | AB | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A217217-003 | AB | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A217217-004 | AB | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A217217-005 | AB | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A217217-006 | AB | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | A217217-001 | AB | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | A217217-002 | AB | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | A217217-003 | AB | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | A217217-004 | AB | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | A217217-005 | AB | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | A217217-006 | AB | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A217217-001 | AB | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A217217-002 | AB | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A217217-003 | AB | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A217217-004 | AB | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A217217-005 | AB | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A217217-006 | AB | 1 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | A217217-001 | AB | 1 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | A217217-002 | AB | 1 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | A217217-003 | AB | 1 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | A217217-004 | AB | 1 | 6a471c1ec25d… |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- Dasatinib
- Listing expiration
- 2027-12-31
Active Ingredients#
| Ingredient | Strength |
|---|---|
| DASATINIB | 140 mg/1 |
Harmonized UNII identifiers#
| Identifier | FDA.report destination |
|---|---|
| RBZ1571X5H | Internal UNII lookup |
Harmonized RxCUI identifiers#
Harmonized SPL set identifiers#
| Identifier | FDA.report destination |
|---|---|
| 4582bf1e-d0c4-88ec-f76c-4670bd7b14ad | Available on FDA.report |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Dasatinib | DASATINIB | BluePoint Laboratories | 02b04c6f-4ea5-4fcb-bf6d-2631d5ab31e4 | 2026-03-05 | Warnings, Adverse reactions | 217217 ANDA217217 |
| Dasatinib | DASATINIB | Quallent Pharmaceuticals Health LLC | 4582bf1e-d0c4-88ec-f76c-4670bd7b14ad | 2026-02-28 | Warnings, Adverse reactions | 217217 ANDA217217 82009-197-30 82009-197 82009019730 |
| Dasatinib | DASATINIB | Biocon Pharma Inc. | 76e1833c-e105-5a3d-0f01-1330d8cc7ae1 | 2025-02-25 | Warnings, Adverse reactions | 217217 ANDA217217 |
Packages#
| Package NDC | 11-digit format | Description | Marketing start | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|
| 82009-197-30 | 82009019730 | 30 TABLET, FILM COATED in 1 BOTTLE (82009-197-30) | 2026-11-02 | No | No | Current |